Prevalence and course of disease after lung resection in primary ciliary dyskinesia:A cohort &amp; nested case-control study by Kouis, Panayiotis et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Prevalence and course of disease after lung resection in primary ciliary dyskinesia
A cohort & nested case-control study
Kouis, Panayiotis; Goutaki, Myrofora; Halbeisen, Florian S.; Gioti, Ifigeneia; Middleton, Nicos;
Amirav, Israel; Barbato, Angelo; Behan, Laura; Boon, Mieke; Emiralioglu, Nagehan;
Haarman, Eric G.; Karadag, Bulent; Koerner-Rettberg, Cordula; Lazor, Romain; Loebinger,
Michael R.; Maitre, Bernard; Mazurek, Henryk; Morgan, Lucy; Nielsen, Kim Gjerum; Omran,
Heymut; Özçelik, Ugur; Price, Mareike; Pogorzelski, Andrzej; Snijders, Deborah; Thouvenin,
Guillaume; Werner, Claudius; Zivkovic, Zorica; Kuehni, Claudia E.; Yiallouros, Panayiotis K.
Published in:
Respiratory research
DOI:
10.1186/s12931-019-1183-y
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Kouis, P., Goutaki, M., Halbeisen, F. S., Gioti, I., Middleton, N., Amirav, I., ... Yiallouros, P. K. (2019). Prevalence
and course of disease after lung resection in primary ciliary dyskinesia: A cohort & nested case-control study.
Respiratory research, 20, [212]. https://doi.org/10.1186/s12931-019-1183-y
Download date: 23. jun.. 2020
RESEARCH Open Access
Prevalence and course of disease after lung
resection in primary ciliary dyskinesia: a
cohort & nested case-control study
Panayiotis Kouis1, Myrofora Goutaki2, Florian S. Halbeisen2, Ifigeneia Gioti1, Nicos Middleton3, Israel Amirav4,25, on
behalf of the Israeli PCD Consortium, Angelo Barbato5, on behalf of the Italian PCD Consortium, Laura Behan6,
Mieke Boon7, Nagehan Emiralioglu8, Eric G. Haarman9, Bulent Karadag10, Cordula Koerner-Rettberg11,
Romain Lazor12,13, on behalf of the Swiss PCD Group, Michael R. Loebinger14, Bernard Maitre15, on behalf of the
French Reference Centre for Rare Lung Diseases, Henryk Mazurek16, Lucy Morgan17, Kim Gjerum Nielsen18,
Heymut Omran19, Ugur Özçelik8, Mareike Price20, Andrzej Pogorzelski16, Deborah Snijders5, on behalf of the PCD
Italian Consortium, Guillaume Thouvenin21, on behalf of the French Reference Centre for Rare Lung Diseases,
Claudius Werner19,26, Zorica Zivkovic22,23, Claudia E. Kuehni2 and Panayiotis K. Yiallouros1,24*
Abstract
Background: Lung resection is a controversial and understudied therapeutic modality in Primary Ciliary Dyskinesia
(PCD). We assessed the prevalence of lung resection in PCD across countries and compared disease course in
lobectomised and non-lobectomised patients.
Methods: In the international iPCD cohort, we identified lobectomised and non-lobectomised age and sex-
matched PCD patients and compared their characteristics, lung function and BMI cross-sectionally and
longitudinally.
Results: Among 2896 patients in the iPCD cohort, 163 from 20 centers (15 countries) underwent lung resection
(5.6%). Among adult patients, prevalence of lung resection was 8.9%, demonstrating wide variation among
countries. Compared to the rest of the iPCD cohort, lobectomised patients were more often females, older at
diagnosis, and more often had situs solitus. In about half of the cases (45.6%) lung resection was performed before
presentation to specialized PCD centers for diagnostic work-up. Compared to controls (n = 197), lobectomised
patients had lower FVC z-scores (− 2.41 vs − 1.35, p = 0.0001) and FEV1 z-scores (− 2.79 vs − 1.99, p = 0.003) at their
first post-lung resection assessment. After surgery, lung function continued to decline at a faster rate in
lobectomised patients compared to controls (FVC z-score slope: − 0.037/year Vs − 0.009/year, p = 0.047 and FEV1 z-
score slope: − 0.052/year Vs − 0.033/year, p = 0.235), although difference did not reach statistical significance for
FEV1. Within cases, females and patients with multiple lobe resections had lower lung function.
Conclusions: Prevalence of lung resection in PCD varies widely between countries, is often performed before PCD
diagnosis and overall is more frequent in patients with delayed diagnosis. After lung resection, compared to
controls most lobectomised patients have poorer and continuing decline of lung function despite lung resection.
Further studies benefiting from prospective data collection are needed to confirm these findings.
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Background
Primary Ciliary Dyskinesia (PCD) is a genetically heteroge-
neous disorder characterized by laterality defects and re-
current respiratory infections [1]. Bronchiectasis may
develop already in childhood [2] and it is usually present
in most adult PCD patients [3]. Late diagnosis is associ-
ated with worse clinical picture, [4–6] although even early
diagnosis is followed by variable courses of lung function
that are not linked to the level of lung function at diagno-
sis [7]. Management varies considerably between centers,
as there are no evidence-based therapeutic guidelines for
PCD [8]. Most of the current treatment protocols are ex-
trapolated from Cystic Fibrosis (CF) studies.
Historically, in CF patients with localized bronchiec-
tasis, lung resection has been proposed as a measure to
decrease infection burden and limit the damage to the
remaining lung [9–11]. However, a recent study from
the US showed no improvement in lung function, hos-
pital admissions or antibiotic use in CF patients after
lung resection [12]. Similarly, a retrospective, small-scale
study in children with non-CF bronchiectasis concluded
that surgical treatment did not affect annual exacerbation
rates and lung function but resulted in reductions the
need for annual intravenous antibiotics [13]. Lung resec-
tion to treat PCD lung disease is generally not recom-
mended, although it can be considered for selected cases
of severe and localized bronchiectasis with recurrent sup-
purative infection, hemoptysis or specific infection [14].
Nevertheless, this approach remains controversial and to
date, only two reports described the clinical course in
PCD patients after lung resection, [5, 15] with conflicting
results. The older study by Smit et al. compared 13 adult
lobectomised PCD patients to 8 adult non-lobectomised
PCD patients and did not find significant differences in re-
spiratory symptoms between the two groups. Despite this,
85% of the lobectomised patients subjectively perceived
the operation as beneficial [15]. A more recent study from
Cyprus, compared 5 lobectomised PCD patients with 7
age-matched non-lobectomised PCD patients and re-
ported that lobectomised patients had a more severe clin-
ical picture and consistently lower lung function across
time compared to non-lobectomised patients [5]. Both
reports were single-center studies with small sample size
and generalizability of their results is limited.
Ideally, the performance of a carefully conducted pro-
spective study would be required to assess the impact of
lung resection in PCD patients. However, due to the low
prevalence of PCD and the rarity of lung resection, this
approach is unrealistic. Alternatively, analysis of retro-
spective international registry data could offer important
answers to this question. We used the international PCD
cohort (iPCD) [16] to assimilate information from a large
number of PCD patients across specialized centers in
order to a) assess the prevalence of lung resection among
PCD patients, b) compare characteristics of lobectomised
and non-lobectomised patients in the iPCD cohort and c)
in a nested case-control study with more detailed data
describe and identify predictors (sex, extent of lung resec-
tion, lung function prior lung resection) of disease course
after lung resection.
Methods
Population and study design
We used a dataset from the iPCD cohort, a large retro-
spective international cohort study of > 3000 PCD pa-
tients. All patients included in the iPCD cohort had
diagnoses of other chronic lung diseases such as cystic
fibrosis and primary immunodeficiency excluded. Add-
itional details on iPCD cohort can be found elsewhere
[16]. The cohort analysis included all patients whose
data on lung resection status were available by May
2017. For each identified lobectomised patient, we ran-
domly selected up to two controls, where available,
stratified by age (±5 years), sex and center. In this man-
ner, the groups of cases and controls were characterized
by similar distributions over different levels of potential
confounding variables such as age, sex and center (fre-
quency matching design) [17]. Selection of cases and
controls is presented in detail in Fig. 1. Information on
available patient data and measurements as well as ethical
approvals permitting the use of patient data is available in
the online data supplement (Additional file 1).
PCD diagnosis
The iPCD Cohort includes data from patients diagnosed
as early as 1964. Since then, availability of diagnostic
tests and diagnostic criteria for PCD have evolved con-
siderably. Originally, diagnosis was largely based on the
presence of the Kartagener triad (bronchiectasis, sinusitis
and situs inversus) and on transmission electron micros-
copy (TEM) findings. With time, High Speed Video Mi-
croscopy (HSVM), as well as nasal nitric oxide (nNO)
and genetic analysis were introduced in the diagnostic
work-up for PCD [18]. Nevertheless, even in recent years
there is considerable variability in the availability of
these tests between countries [8]. Towards better defin-
ing our study population, we classified all identified
lobectomised patients and PCD controls in three diag-
nostic groups according to the recent guidelines of the
ERS PCD Diagnostics Task Force [19]. More specifically,
we classified PCD patients a) as “definite PCD” if they
had hallmark EM findings and/or biallelic PCD genetic
mutations, b) as “PCD highly likely” if they had abnormal
HSVM findings and/or low nNO (using a cut-off of 77 nl/
min as suggested by Leigh MW et al., 2013), and c) as
“clinical PCD” if they had a clinical phenotype suggestive
of PCD but the PCD diagnostic algorithm was incomplete
or diagnostic results were negative or ambiguous. All
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patients classified as “clinical PCD” were excluded from
statistical analysis and both the cross-sectional and longi-
tudinal analysis is based on patients classified only as “def-
inite PCD” or “PCD highly likely”.
Analysis
iPCD cohort study
The prevalence of lung resection in PCD was calculated
as percentage of all PCD patients in the dataset, as well
as percentage of all PCD patients per study center.
Similarly, prevalence of lung resection among adults
(≥18 years) with PCD was calculated as percentage of
total adult PCD patients in the dataset and per country.
Basic characteristics of lobectomised patients were
summarized as percentages or as medians and inter-
quartile ranges (IQR), as appropriate. Differences in the
distribution of characteristics between lobectomised and
non-lobectomised patients in the iPCD cohort were inves-
tigated using chi-square test for categorical variables and
Wilcoxon Sum Rank test for continuous variables.
Fig. 1 Participants selection and data availability. Flowchart of participants’ selection and data availability. From the 22 centers (3415 patients)
that were included in the iPCD cohort, 20 centers (2896 patients) agreed to participate and provided data to the study. Of these 163 were
patients that underwent lung resection. Of the remaining 2733 patients, we randomly selected 265 controls stratified by age (± 5 years), sex and
center. Data availability for cross-sectional and longitudinal case-control analysis as well as data availability for the within cases pre-post lung
resection analysis is also displayed
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Nested case-control study - cross-sectional comparisons
Diagnostic results and clinical characteristics of lobec-
tomised patients (at first available post-lobectomy
assessment) and non-lobectomised controls were com-
pared using paired sample t-test and Wilcoxon Sum
Rank test for normally and non-normally distributed
variables respectively.
Nested case-control study – longitudinal comparisons
We explored disease course post-lung resection in lobec-
tomised PCD patients compared to controls, using serial
measurements of FEV1, FVC and BMI in a longitudinal
mixed effects model. The model was defined by fixed
effects for lung resection and age, an interaction term
between lung resection and age and by random effects
for intercepts and slopes (change per year). In addition,
the frequency of positive sputum cultures for Pseudo-
monas aeruginosa was compared between cases and
controls across different age groups (5–10, 10–15,
15–20, 20–30 and 30+) by chi square test.
Predictors of disease course within cases – longitudinal
comparisons
We also explored the effect of sex and number of lobes
resected as potential predictors of adverse clinical course
within the lobectomised group with two separate sub-
group analyses. In the first subgroup analysis by sex, ser-
ial measurements of FEV1, FVC and BMI were analyzed
with longitudinal mixed effect model defined as above
and using a binary fixed effect term for sex while in the
second subgroup analysis, the longitudinal mixed effect
model used a binary fixed effect term for number of
lobes resected.
Pre- and post- lung resection comparisons
In a small subgroup of lobectomised patients, we ana-
lyzed available lung function and BMI data before and
after lung resection with the aim to provide insight to
the critical question whether the adverse disease course
of lobectomised patients is due to lung resection or to
more severe disease phenotype prior lung resection.
FEV1, FVC and BMI z-scores were plotted across time
and the mean pre- and post- lung resection values were
compared using paired samples t-test. Furthermore,
mean lung function z-scores of lobectomised patients at
their last assessment prior to lung resection were com-
pared with the mean of lung function measurements in
controls obtained when they had the same age, using
two-way analysis of variance to adjust for the effect of
age. Lastly, the longitudinal mixed model analysis was
repeated for this small group of patients and for an equal
number of controls matched based on propensity score
calculated using the variables for level of diagnostic cer-
tainty, sex, age at presentation and positive sputum
culture. The calculation of the propensity score was car-
ried out using the STATA “pscore” command [20].
Pairwise deletion was used to handle missing data in
an analysis by analysis basis. Statistical comparisons were
performed using STATA 12 (StataCorp, TX) and graphs
were generated with Microsoft Excel.
Results
iPCD cohort study - prevalence of lung resection and
patient characteristics
From 2896 PCD patients, followed-up in 20 centers
across 15 countries, 163 (5.6%) were reported to have
undergone lung resection (Fig. 1). Among adults with
PCD, lung resection was reported for 127 patients out of
1431 (8.9%), whereas in the pediatric age-group only 36
out of 1465 (2.5%) underwent surgical treatment. Wide
variation was observed in lung resection prevalence
among PCD centers (range: 0 to 17%, Fig. 2, absolute
numbers in Additional file 1: Table S1).
Lobectomised patients were significantly older at the
time of the study (median age 24.9 vs 18.6 years, p-
value< 0.001) and included more females (55.4% vs
49.0%, p-value = 0.150) than the non-lobectomised iPCD
cohort (Table 1). In addition, lobectomised patients pre-
sented to the PCD specialist centers at an older age
(11.5 vs 8.8 years, p-value< 0.001) and had less frequently
laterality defects (25% vs 44.1%, p-value< 0.001) than the
rest of the cohort. The number of lung resection proce-
dures performed per decade in iPCD cohort patients
seemed to be increasing (p-value < 0.001) in the last de-
cades (Table 1). In most cases (83.5%), lung resection
was performed when the patients were in childhood and
in about half of the cases (45.6%) lung resection was
performed before presentation to the specialized PCD
centers for diagnostic work-up. Stratification by lung re-
sections performed before or after presentation to a
PCD center demonstrated that before 1990, almost all
lung resections occurred prior presentation to a PCD
center (100% < 1969, 73% during 1970–1979 and 89%
during 1980–1989). During the period 1990 to 2010, ap-
proximately 50% of lung resections occurred prior pres-
entation to a PCD center, as opposed to only 18% after
2010 (Additional file 1: Table S3). In a quarter of the
cases (22.1%), lung resection was extended beyond one
lobe, involving segments in 2 to 4 lobes, whereas the most
frequently resected segments were at the right middle lobe
(48.8%) and left lower lobe (27.3%) (Table 1).
Nested case-control study – cross-sectional comparisons
In total, 265 center, age and sex-matched non-lobectomised
PCD patients were selected as controls from the 20
participating centers (Fig. 1). The targeted 1:2 cases-
controls ratio was not achieved for every case due to
lack of eligible controls in some centers. After exclusion
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of patients characterized by ambiguous or incomplete
diagnostic results (“clinical PCD”), a total of 130 lobec-
tomised and 197 controls were compared. Although
nasal nitric oxide was low in both cases and controls, it
was somewhat higher in lobectomised patients (me-
dian: 16 vs 10 nl/min, p-value = 0.013). Ciliary ultra-
structure and motility were not different between the
two groups (Additional file 1: Table S2). Cross-
sectional comparisons of clinical characteristics of
controls at presentation with those of lobectomised
patients at their first available post-lobectomy assess-
ment, revealed higher prevalence of bronchiectasis
(95.7% vs 76.1%, p-value = 0.004) and chronic cough
(96.8% vs 88.4%, p-value = 0.023) but less wheezing
(39.7% vs 59.2%, p-value = 0.016) in the lobectomised
cohort (Table 2). Compared to controls, lobectomised pa-
tients had lower FVC (− 2.41 vs − 1.35, p = 0.0001) and
FEV1 (− 2.79 vs − 1.99, p = 0.003) z-scores at baseline (first
post-lobectomy assessment) but no difference in BMI z-
scores (0.03 vs − 0.09, p-value = 0.599).
Nested case-control study – longitudinal comparisons
In a longitudinal mixed model analysis, we included 39
lobectomised PCD patients and 43 non-lobectomised
controls who had available two or more repeated measure-
ments of FVC, FEV1 and BMI. The mean time interval with
available longitudinal measurements for each lobectomised
patient was 9.20 years (95% CI: 7.40–11.01) while the mean
interval for each control patient was 10.82 years (95% CI:
8.22–13.41). The difference between the two values was not
statistically significant (p-value: 0.310). We found no differ-
ence at the level (intercept) of FVC (− 1.00 vs − 0.75, p-
value = 0.489) and FEV1 (− 1.47 vs − 1.12, p-value = 0.346)
between lobectomised and control patients (Table 3).
However, both control and lobectomised groups, displayed
loss of lung function with time. Although lung function de-
cline in the lobectomised patients after lung resection was
somewhat steeper in terms of FVC (z-score slope: − 0.037/
year vs – 0.009/year, p= 0.047) and FEV1 (z-score slope: −
0.052/year vs − 0.033/year, p= 0.235), the difference in the
latter did not reach statistical significance. In contrast, BMI
remained stable post-lung resection in lobectomised patients
compared to controls (z-score slope: 0.024/year vs 0.015/
year, p= 0.507) (Table 3). Lobectomised patients had also
more frequent (77/263, 29.3%) positive sputum cultures for
Pseudomonas aeruginosa compared to controls (66/487,
13.6%) (p-value< 0.001) that was evident in age-groups after
the age of 10 years (Additional file 2: Figure S1).
Fig. 2 The frequency of lung resection among patients in the iPCD cohort by participating centers. The prevalence of lung resection among PCD
patients in the iPCD cohort across different centers. Prevalence among all PCD patients is denoted with dark color and prevalence among adult
PCD patients is denoted with lighter pattern color. Absolute numbers are displayed in Additional file 1: Table S1 (Additional file 1). AU: Australia;
BE: Belgium; CH: Switzerland; CY: Cyprus; DE1: Bochum, Germany, DE2: Muenster, Germany; DE3: Hannover, Germany; DK: Denmark; FR: France; IL:
Israel; IT: Italy; NL: the Netherlands; NO: Norway; PL: Poland; RS: Serbia; TR1: Istanbul, Turkey; TR2: Ankara, Turkey; UK1: Paediatric Pulmonology
Dept, Brompton, UK; UK2: Adult Pulmonology Dept, Brompton, UK; UK3: Southampton, UK
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Predictors of disease course
Within lobectomised patients, subgroup analysis by sex
indicated sharp differences between males and females in
the level (intercept) of FEV1 (− 0.94 vs − 1.96, p-value =
0.064) and FVC (− 0.68 vs − 1.65, p-value = 0.125) z-scores
after lung resection, with females having significantly
worse lung function. Patients of both sexes continued
to lose lung function with time after lung resection
but changes were somewhat steeper in males, with sig-
nificantly worse slope for FEV1 (− 0.08/year vs − 0.03/
year, p-value = 0.026) but not for FVC (− 0.05/year vs −
0.021/year, p-value = 0.263) (Table 4). In subgroup analysis
by the number of lobes resected, we found unfavorable
differences at the level of FVC (− 0.75 vs − 2.49, p-value =
0.040) and FEV1 (− 1.10 vs − 2.89, p-value = 0.012) z-scores
intercepts in patients who underwent multiple lobes resec-
tion in comparison to patients who had only one lobe
resected. However, subsequent lung function decline with
ageing was not different between the two groups (Table 4).
In a subgroup of 18 lobectomised patients, lung func-
tion and BMI data before and after lung resection were
available. The basic characteristics of these 18 patients
are presented in Additional file 1: Table S4. The individ-
ual FVC, FEV1 and BMI z-scores trends as well as the
average trend for these patients across time, before and
after lung resection appear in Fig. 3 in comparison to
Table 1 Features of lobectomised and non-lobectomised patients in the iPCD cohort
Variable Lobectomised PCD
(n = 130) Median (IQR)
iPCD Cohort (n = 2733)a
Median (IQR)
p-value
Age at Presentation (n = 118) 11.5 (6.5, 20.5) 8.8 (4.0, 15.8) < 0.001†
Current Age (n = 130) 24.9 (18.1, 40.1) 18.6 (12.1, 28.3) < 0.001†
% Female 72/130 (55.4%) 1302/2661 (48.9%) 0.150‡
Situs Inversus 27/108 (25.0%) 787/1783 (44.1%) < 0.001‡
Age at lung resection (n = 121) 11.9 (7.7, 16.0)
Lung resection prior to presentation 52/114 (45.6%)
Lung resection in childhood 101/121 (83.5%)
Frequency of lung resection performance
per decade (n = 121)
< 1969 4 < 0.001‡
1970–1979 11
1980–1989 9
1990–1999 24
2000–2009 34
2010–2017 39
Extent of lung resection (n = 95) One Lobe: 74/95
(77.9%)
Two lobes: 17/95
(17.9%)
Three Lobes: 2/95
(2.1%)
Four Lobes: 2/95
(2.1%)
Site of lung resectionb (n = 95) RML: 59/121 (48.8%)
LLL: 33/121 (27.3%)
RLL: 13/121 (10.7%)
Lingula: 9/121 (7.4%)
RUL: 5/121 (4.1%)
LUL: 2/121 (1.7%)
Denominators indicate number of subjects with available data on the specific parameter
RUL: Right Upper Lobe, RML: Right Middle Lobe, RLL: Right Lower Lobe, LUL: Left Upper Lobe, LLL: Left Lower Lobe
aFull iPCD cohort that participated in the study, excluding lobectomised patients (May 2017)
bDenominator reflects the total number of resected lobes. Some patients had more than one lobe resected. For one patient (one with one lobe resected) the
exact site was not reported
†Wilcoxon Sum Rank Test
‡Pearson Chi Square Test
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the respective trends of propensity score matched con-
trols. Average lung function z-scores before lung resec-
tion were significantly higher when compared to z-
scores after lung resection (FEV1: − 1.77 Vs − 2.69 p-
value < 0.001, FVC: − 1.16 Vs − 1.99, p-value = 0.003),
whereas BMI z-scores pre and post-lung resection did
not differ (0.33 Vs 0.22, p-value = 0.669). Mean lung
function z-scores of lobectomised patients at their last
assessment prior lung resection did not differ from the
mean lung function of matched non-lobectomised patients
obtained when they had the same age (mean difference in
FEV1: 0.00075, p-value = 0.820, mean difference in FVC:
0.34, p-value = 0.512). The analysis of FVC, FEV1 and BMI
z-score decline between the 18 lobectomised patients and
their respective propensity score matched controls demon-
strated a steeper decline per year in the lobectomised
patients especially in FVC z-scores (− 0.080 Vs 0.010, p-
value = 0.006) and not so in FEV1 z-scores (− 0.099 Vs −
0.029, p-value = 0.071) (Additional file 1: Table S5).
Discussion
In this study, we present the first cumulative retrospective
data on lung resection in a large number (n = 163) of PCD
patients, reported from 20 centers across 15 countries.
Table 2 Cross-sectional characteristics of lobectomised PCD patients (on first post-lung resection assessment) compared to matched
controls
Lobectomised PCD (n = 130) Controls PCD (n = 197) p-value†
FVC Z score − 2.41 (− 2.91, − 1.90) − 1.35 (− 1.70, − 1.00) 0.0001‡
FEV1 Z score −2.79 (− 3.25, − 2.32) −1.99 (− 2.32, − 1.65) 0.003‡
BMI Z score 0.03 (− 0.34, 0.40) − 0.09 (− 0.38, 0.19) 0.599‡
Sputum Culture
Any Pathogen 60/73 (82.2%) 74/92 (80.4%) 0.774
Pseudomonas 20/73 (27.4%) 15/92 (16.3%) 0.083
Bronchiectasis 44/46 (95.7%) 86/113 (76.1%) 0.004
Congenital Heart Disease 10/86 (11.6%) 13/126 (10.3%) 0.763
NRDS 37/78 (47.4%) 51/114 (44.7%) 0.712
Chronic Cough 92/95 (96.8%) 99/112 (88.4%) 0.023
Sputum 78/82 (95.1%) 73/81 (90.1%) 0.222
Wheezing 25/63 (39.7%) 58/98 (59.2%) 0.016
Pneumonia 11/66 (16.7%) 35/120 (29.2%) 0.059
Hemoptysis 2/58 (3.5%) 0/67 (0%) 0.125
Rhinorrhea 68/79 (86.1%) 111/123 (90.2%) 0.363
Denominators indicate number of subjects with available data on the specific parameter NRDS: Neonatal Respiratory Distress Syndrome †Pearson Chi Square Test,
with the exception of FVC, FEV1 and BMI ‡Paired Samples T test
Table 3 Change in lung function and BMI over time (post-lung resection) in lobectomised PCD patients (n = 39) and controls (n = 43)
Outcome Group Intercept (95% CI) p-value Change per year (95% CI) p-value*
FVC Z score Lobectomised −1.00 0.489 −0.037 0.047
(−2.17, −0.17) (−0.09, 0.01)
Controls −0.75 −0.009
(−1.20, − 0.29) (− 0.03, 0.01)
FEV1 Z score Lobectomised −1.47 0.346 − 0.052 0.235
(−2.65, −0.28) (− 0.10, 0.00)
Controls −1.12 −0.033
(−0.05, − 0.02)(−1.58, −0.66)
BMI Z score Lobectomised −0.44 0.790 0.024 0.507
(−1.49, 0.61) (−0.02, 0.07)
Controls −0.35 0.015
(−0.74, 0.04) (−0.002, 0.03)
* P value for interaction, testing whether the relationship between independent variables (FVC, FEV1, BMI) and time is different between Lobectomised
and Controls
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Despite the anecdote that lobectomy is uncommon in
PCD, in this representative sample of 2896 PCD patients,
we report an overall prevalence of lobectomy nearly 6%,
whereas in adult PCD populations from one fifth of the
centers prevalence exceeds 20%. Prevalence rates of lung
resection in single-center reports, [9, 10, 12] in CF cohorts
are much lower (3%) compared to our series. There are
no large scale, international data either on the prevalence
or on long-term outcomes of lung resection in CF.
The characteristics of lobectomised patients provide
possible explanations for the high prevalence of lung re-
section in PCD. Lobectomised PCD patients were diag-
nosed at an older age and had much less frequently
laterality defects, indicating the difficulty to establish the
diagnosis in these patients, in comparison to the rest of
the iPCD cohort. In fact, in about half of the cases, lung
resection was performed prior diagnosis, which suggests
that in these patients the decision of lung resection was
taken at a time when the nature of chronic lung disease
was probably unknown. Interestingly, lung resections
prior to diagnosis were performed more frequently dur-
ing the earlier decades with available data (before 1990),
in a period where awareness and knowledge about PCD
was scarce [4]. This seems to have changed in later
decades (after 1990), where the opposite trend was ob-
served with gradually less lung resections performed
prior to presentation. After 2010, it appears that very
few PCD patients underwent lung resection prior to
presentation (18%), although the latter figure may be an
underestimation of the reality as some undiagnosed
PCD patients undergoing lung resection in the last few
years might have not been diagnosed by PCD centers
yet. Differences in age of diagnosis as well as in surgical
and medical care of bronchiectasis across countries may
explain the differences in the rates of lung resection
across countries. Persistent atelectasis and consolidation,
especially at the middle and lower lobes, are common
features in PCD [21, 22]. In comparison to CF, MRI and
Table 4 Subgroup Analysis: Change in lung function and BMI over time (post-lung resection) by sex (n = 39) and by extent of lung
resection (n = 35)
Outcome Subgroup Intercept (95% CI) p-value Change per year
(95% CI)
p-value*
FVC Z score Males −0.68 0.125 −0.049 0.263
(−1.57, 0.22) (−0.09, − 0.01)
Females −1.65 −0.021
(−3.79, 0.49) (−0.11, 0.07)
FEV1 Z score Males −0.94 0.064 −0.08 0.026
(−1.71, −0.17) (−0.12, − 0.05)
Females −1.96 −0.03
(−3.81, −0.11) (−0.11, 0.04)
BMI Z score Males −0.04 0.180 0.02 0.967
(−0.71, 0.62) (−0.01, 0.05)
Females −0.68 0.02
(−2.27, −0.92) (−0.05, 0.09)
FVC Z score Single Lobe −0.75 0.040 −0.03 0.645
(−1.38, −0.13) (−0.06, − 0.01)
Multiple Lobes −2.49 −0.05
(−4.79, −0.21) (−0.14, 0.04)
FEV1 Z score Single Lobe −1.10 0.012 −0.06 0.955
(−1.61, −0.60) (−0.08, − 0.03)
Multiple Lobes −2.89 −0.06
(−4.78, −0.99) (−0.14, 0.02)
BMI Z score Single Lobe −0.15 0.456 0.02 0.042
(−0.64, 0.35) (0.01, 0.04)
Multiple Lobes −0.62 −0.02
(−2.35, 1.12) (−0.08, 0.04)
*P value for interaction, testing whether the relationship between independent variables (FVC, FEV1, BMI) and time is different within the lobectomised patients
between males and females (Subgroup Analysis 1) and between single and multiple lobes resected (Subgroup Analysis 2)
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CT scores for lung collapse/consolidation in PCD are of
higher severity, [23–25] which may be a contributing
factor to the more frequent performance of lung resec-
tion in PCD. RML was by far the most frequently
resected lobe, indicating the frequency and severity of
the involvement of this lobe in PCD lung disease.
Previous reports found associations between bronchi-
ectasis development in RML and unfavorable clinical
outcomes [26, 27].
Our study also provides important insight in PCD dis-
ease course after lung resection. Lobectomised patients
have higher prevalence of bronchiectasis and lower FVC
and FEV1 at first post-lung resection assessment when
compared to their matched controls, as may be expected
after loss of lung tissue. Despite performing lung resec-
tion to treat chronic lung disease complications, most
lobectomised patients continue to display loss of lung
function with time after surgery, which is somewhat
Fig. 3 Lung function and BMI z-scores across time in PCD lobectomised patients (n = 18), before and after lung resection and propensity score
matched controls (n = 18). The left panel displays the trend of lung function and BMI z-scores across time in 18 lobectomised PCD patients with
available data before and after lung resection. The dashed red line represents the average trend for all 18 patients. The dashed black line denotes
the zero z-score level. The overall mean pre-resection lung function z-scores were significantly higher compared to post-resection lung function
z-scores (FEV1: − 1.77 Vs − 2.69 p-value < 0.001, FVC: − 1.16 Vs − 1.99 p-value: 0.003). BMI z-scores did not differ significantly (0.33Vs 0.22 p-value:
0.669). The right panel displays the trend of lung function and BMI z-scores across time in 18 propensity score matched controls
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steeper in terms of FVC but not FEV1, in comparison to
non-lobectomised controls. Knowledge of this may have
important implications at the stage of considering the
decision to undertake such an intervention. This trend
was also evident when we compared the course of lung
function between the 18 patients that had available lung
function data pre and post lung resection and 18 pro-
pensity score matched controls. Lobectomised patients
also display more frequent growth of Pseudomonas aeru-
ginosa in their sputa, which was shown in one adult
PCD study [28] to be a poor predictor of lung function,
although this was not confirmed in other studies [29].
Although a previous iPCD study [30] showed association
of lung function with BMI, we found that BMI had a
stable course in our lobectomised and control groups.
Patients who underwent multiple lobes resection had
much lower level of lung function in comparison to
those with only one lobe resected. This is not surprising
given that more lung tissue was removed, but interest-
ingly these patients display similar loss of lung function
after lung resection with patients who underwent single
lobe resection. Being female has been recently acknowl-
edged as a predictor for poor lung function in adult
PCD patients, [28] and it is a well-known predictor of
adverse disease course in CF. [31, 32] In this series, be-
ing female is associated with adverse post-lung resection
lung function, although loss of lung function in subse-
quent years is somewhat more profound in males who
seem to lose more rapidly thereafter the excess lung
function they have in comparison to females.
In a small subgroup of 18 patients, we had some indi-
cations that the mean lung function prior lung resection
declined after surgery. However, lung volume reduction
by the operation is confounding the value of lung func-
tion as a reliable parameter for the comparison of dis-
ease course pre and post operation. Pre-resection lung
function was similar to the lung function of matched
non-lobectomised PCD patients, suggesting that at least
in terms of lung function the disease course before
surgery was similar to non-lobectomised patients. Unfor-
tunately, we have no detailed data on other important
clinical indices prior lung resection, such as extent of
bronchiectasis and clinical morbidity that are also key
parameters of clinical severity. Interestingly, in contrast
to the adverse lung function trend in the whole group,
evaluation of individual FVC and FEV1 trends before
and after lung resection in a minority of patients demon-
strated improved lung function after surgery. This
finding suggests that surgical intervention may be a
worthwhile option in carefully selected PCD patients
with severe localized symptomatic bronchiectasis. More
studies are needed to elicit predisposing factors for the
favorable post-lung resection course in this minority of
patients.
The major strength of this study is the provision of data
on a large, representative, international sample of PCD pa-
tients who underwent surgery to treat bronchiectasis, dem-
onstrating continuing lung function decline after surgery.
However, the study was retrospective and although effort
was made to collect all relevant data based on a predefined
protocol, not only from the iPCD registry but also by con-
tacting the local principal investigators at the collaborating
centers, we cannot exclude that some data were missed. In
addition, given its retrospective nature, the study did not
benefit from a standardized diagnostic protocol (not all PCD
patients underwent the same tests across different centers)
or standardized lung function testing procedures as de-
scribed by the ERS/ATS recommendations [33]. The multi-
center nature of the study also might introduce center-
related heterogeneity in the collected parameters that we
tried to control by recruiting for each lobectomised patient
two controls matched for age, sex and center, although this
was not possible for all cases. Furthermore, participating pa-
tients had different stages of disease and underwent different
kinds of surgical intervention, introducing variabilities that
may affect the outcomes, which are impossible to assess and
control in a retrospective study. Overall, although this is the
first study that examines and provides insights into the prag-
matic outcomes of lung resection in a large number of PCD
patients across many international centers, the retrospective
nature of the data as well as the small sample size available
for some of the subgroup analyses warrant caution in the
generalization of the results.
Conclusions
Prevalence of lung resection for treating bronchiectasis in
PCD varies widely between countries and is unexpectedly
high in some cohorts of adult patients. Historically, lung
segments were removed from patients who were subse-
quently diagnosed with PCD. These patients tended to not
have other clues for the diagnosis such as situs inversus.
PCD diagnosis should be considered in all patients with
bronchiectasis, especially those with bronchiectasis severe
enough for lobectomy to be considered. This study demon-
strates that lung resection in PCD, especially in female pa-
tients, is associated with more severe impairment of lung
function, which continues to decline after lung resection.
Further studies, benefiting from prospective data collection
are needed to confirm these findings.
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